Acute Haemodynamic Study of TPN171H in Patients With Pulmonary Arterial Hypertension

  • STATUS
    Recruiting
  • End date
    Dec 6, 2022
  • participants needed
    60
  • sponsor
    Vigonvita Life Sciences
Updated on 29 December 2021
hypertension
heart disease
connective tissue disease
tadalafil

Summary

This study is a phase IIa proof-of-concept study to evaluate the effect of single-dose TPN171H tablets on acute haemodynamic parameters in patients with pulmonary arterial hypertension.The trial is expected to include 60 patients, divided into 6 groups, according to 1:1:1:1:1:1 into the placebo group and the test drugs 2.5mg, 5mg, 10mg group, tadalafil tablets 20mg, 40mg group, each group 10 cases.

Description

This study is a multi-center, randomized, placebo and positive controlled phase IIa proof-of-concept study to evaluate the effect of single-dose TPN171H tablets on acute hemodynamic parameters in patients with pulmonary arterial hypertension.The trial is expected to include 60 patients, divided into 6 groups, according to 1:1:1:1:1:1 into the placebo group and the test drugs 2.5mg, 5mg, 10mg group, tadalafil tablets 20mg, 40mg group, each group 10 cases. During the screening period, the tube placement period, and the observation period, the patients will conduct various inspections and evaluation observations as required.

The Swan-Ganz floating catheter and echocardiography were used to evaluate the efficacy of TPN171H; PK parameters: including Tmax, Cmax, AUC0-t , t1/2,CL/F, Vz/F, z; Safety evaluation indicators include: vital signs, physical examination, laboratory examination (blood routine, blood biochemistry, blood gas analysis), 12-lead ECG, adverse events.

Details
Condition Pulmonary Arterial Hypertension
Treatment Placebo, Tadalafil, TPN171H
Clinical Study IdentifierNCT04483115
SponsorVigonvita Life Sciences
Last Modified on29 December 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients aged 18 to 75
Patients who have voluntarily decided to participate in this study, and signed the informed consent form
Patients who are able to understand and follow study plans and instructions
Patients with symtomatic PAH (Group1), a pulmonary vascular resistance (PVR) > 3 Wood, a mean pulmonary artery pressure (mPVP) 25 mmHg and a pulmonary artery wedge pressure (PAWP) 15 mmHg either due to
Idiopathic PAH (IPAH)
Familial PAH
Associated PAH due to drugs or toxins
Associated PAH due to connective tissue disease
Associated PAH due to congenital heart disease, if patients underwent surgical correction more than 1 year prior to screening
Have a current diagnosis of being in WHO functional class II or III
Patients who are willing to take proper contraceptive during the study and within 3 months after the study completed

Exclusion Criteria

All types of PH except subtypes of Group1 specified in the inclusion criteria
Moderate to severe COPD (FEV1 < 60% predicted)
Moderate to severe restrictive lung disease (FVC < 70% predicted)
Pre-treatment with PAH therapy within the last 1 months before the screening visit (including endothelin receptor antagonists, PDE5 inhibitors, guanylate cyclase agonist and prostacycline analogues)
A "positive" response to acute vasodilator testing
Coagulation dysfunction (defined as activated partial thromboplastin time and international normalized ratio are both >1.5 times upper limit normal) or patients with potential bleeding risk
Hepatic dysfunction indicated by: serum bilirubin>3 times upper limit normal, ALT and AST>2.5 times upper limit normal
Renal insufficiency (creatinine clearance<30 mL/min)
Systolic blood pressure<90 mmHg at screening
QT prolongation at screening, whose values (QTcF) exceeding 450 msec in males and 470 msec in females
Have enrolled in/or have a plan of an exercise training program for pulmonary rehabilitation before the screening visit/or during the study
Patients who have a recent (within 3 months) history of abusing alcohol or illicit drugs
Body weight<40 kg
Patients who have participated in a clinical study involving another investigational drug within 1 month before the screening visit
For any other reasons that affect compliance with the study protocol, especially the long-term monitoring of floating catheters, according to the decision of investigators
HBV, HCV, HIV or Tp infection
Patients with gastrointestinal, urinary, reproductive, immunologic, endocrine, or central nervous system disease that, in the opinion of the investigator, will affect the study
Have a history of malignancies within 2 years, except for a cured basal cell or skin squamous cell carcinoma
Pregnant women, or breast feeding women
Patients with hypersensitivity to iloprost or any of the excipients
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note